Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.

Suzhou Ribo Life Science Co., Ltd. announced the company has received the approval from the CDE of the NMPA for the clinical trial application of its innovative PCKS9 targeting oligonucleotide drug product RBD7022 to conduct the First-In-Human clinical trial in China.

Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.

Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide Therapeutics

Ribocure Pharmaceuticals, the first overseas R&D center of Ribo based in Sweden, announces it will move in and open a clinical trial unit at GoCo Clinic - where both patient care and research will be conducted when it’s ready in the spring of 2023.

Li-Ming Gan, Former VP & Head of Global Clinical Development at AstraZeneca, Joined Ribo as President of Global R&D and CMO

Suzhou Ribo Life Science Co., Ltd. recently announced the Prof. Li-Ming Gan, the former Vice President and head of global clinical development for cardiovascular, renal and metabolism area at AstraZeneca CVRM R&D headquarter in Sweden, has joined Ribo and will serve as the President of Global R&D and Chief Medical Officer since 1st of Jan 2022.

Ribo Completed Two Phase II Clinical Studies in China for Evaluation of Effects of ISIS 449884 in Patients with Type 2 Diabetes Mellitus on Either Life-Style Intervention Only or Metformin Background Treatment

Suzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).